News
-
Aspire Biopharma, Inc. Engages CTM Advisory, Ltd., and Receives Advisory Engagement from Spartan Capital Securities, LLC to Explore NASDAQ Listed Company Merger
HUMACAO, PR, March 20, 2024 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the engagement of CTM Advisory, Ltd. and has received an advisory engagement and expects to engage Spartan Capital Securities, LLC to manage the merger transaction. CTM Advisory, has been engaged by Aspire, to use its expertise…
-
Aspire Biopharma, Inc. Signs Pharmaceutical Development Agreement with Glatt Air Techniques, Inc.
HUMACAO, PR, January 18, 2024 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that it has organized and solidified its timeline for its contemplated 505(b) fast track FDA Trial on its initial product Instaprin. Aspire will be meeting with Glatt Air Techniques, its development and production partner team, in…
-
![]()
Aspire Biopharma, Inc. Announces Newly Appointed Medical Advisory Board Members
HUMACAO, PR, September 5, 2023 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the addition of three new members to its Medical Advisory Board. Aspire Biopharma, Inc. is excited to announce the addition of three new highly qualified advisors to its Medical Advisory Board, including…
-
![]()
Aspire Biopharma, Inc. Completes Stability Study of Instaprin Test Formulation
HUMACAO, PR, June 21, 2023 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that as a material part of its Development Agreement and partnership with Glatt Air Techniques, Inc. (“Glatt”), it has successfully completed a six- month the stability and solubility study of its aspirin-based product Instaprin. Working under…
-
![]()
Aspire Biopharma, Inc. Announces Newly Appointed Board of Directors Members
HUMACAO, PR, May 25, 2023 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the election results and appointment of two new Board of Directors members effective Thursday, May 25, 2023. On Thursday, May 25, 2023, the shareholders of Aspire Biopharma, Inc., in a unanimous vote,…
-
![]()
Aspire Biopharma, Inc. and Glatt Air Techniques, Inc. Scientists Create Test Batch of Instaprin
HUMACAO, PR, November 11 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that through its Development agreement and in connection with domain expert scientists from Glatt Air Techniques, Inc. (“Glatt”), Aspire and Glatt has completed the development of a “test batch” of its aspirin based product Instaprin. Working…
-
![]()
Aspire Biopharma, Inc. Signs Pharmaceutical Development Agreement with Glatt Air Techniques, Inc.
HUMACAO, PR, July 7, 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that it has entered a pharmaceutical product Development Agreement with Glatt Air Techniques, Inc. (“Glatt”). The Development Agreement solidifies our strong partnership with Glatt, a world class manufacturing firm specializing in pharmaceutical and other industries, for…
-
![]()
Aspire Biopharma, Inc. Continues to Build a World Class Team
HUMACAO, PR, May 17, 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the addition of Nancy Taylor, Esq., to its highly skilled team of professional advisors. Aspire Biopharma, Inc. is excited to announce securing an engagement with Nancy Taylor, Esq., the Chair of the…
-
![]()
Aspire Biopharma, Inc. Continues to Build a World Class Team
HUMACAO, PR, May 4, 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the addition of Michael Shuster, Esq., to its highly skilled team of professional advisors. Aspire Biopharma, Inc. is excited to announce securing the engagement of Michael Shuster, Esq., partner in the Life…
-
![]()
Aspire Biopharma, Inc. Acquires Technology Assets from Instaprin Pharmaceuticals, Inc.
HUMACAO, PR, March 28, 2022 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced the acquisition of the intellectual property assets (“IP”) of Instaprin Pharmaceuticals, Inc.(“Instaprin”). The acquisition of Instaprin Pharmaceuticals’ intellectual property assets includes bringing groundbreaking drug delivery technology to the Aspire portfolio. In the transaction, Aspire acquired the…
